



Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy

Cambridge, UK, 7th July – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics announces that it has signed a pre-clinical collaboration agreement with Orano Med, a nuclear biotech company developing innovative targeted therapies in oncology.

Orano Med is developing a new generation of Targeted Alpha Therapies (TAT) using the unique properties of lead-212 (²¹²Pb), a rare radioisotope. With this innovative approach, Orano Med is generating novel therapeutics capable of specifically recognising and destroying cancer cells while limiting the impact on nearby healthy tissues, a cutting-edge treatment for cancers with high unmet need.

Crescendo and Orano Med are working to exemplify the benefit of using Humabody V_H for precise targeting of Orano Med's TAT.

Theodora Harold, CEO of Crescendo Biologics, commented:

“Orano Med is one of the leaders in the field of nuclear medicine. Collaborating on its Targeted Alpha Therapy is an exciting opportunity for Crescendo to demonstrate the advantages of Humabody V_Hs for exquisitely targeted delivery of a potent alpha-emitting payload. We welcome the opportunity to work with the team at Orano Med.”

-Ends-

For more information, please contact:

Crescendo Biologics

Theodora Harold, CEO
+ 44 (0)1223 497140
info@crescendobiologics.com

Instinctif Partners

Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

Orano Med

Imane El Bettioui, Communication Manager
Imane.elbettioui@oranomed.com



About Crescendo Biologics

Crescendo Biologics is a T cell enhancing company. Crescendo develops potent, truly differentiated Humabody® therapeutics with a focus on innovative, targeted T cell approaches in oncology.

Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel CD137-PSMA-HSA trispecific for the selective activation of tumour-specific T cells exclusively within the tumour microenvironment. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity and is on track to enter the clinic in 2020.

The Company's ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® V_H). These robust molecules can be configured to engage therapeutic targets in such a way that they deliver novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital and Astellas.

For more information, please visit the website: www.crescendobiologics.com

About Orano Med

Orano Med (formerly AREVA Med) is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (212Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine that recognizes and destroys cancer cells while limiting the impact on nearby healthy cells. With its partners, Orano Med pursues the development of effective therapies to address patients' needs.

More information about Orano Med: www.oranomed.com. Follow @OranoMedMed on Twitter.